Hims & Hers Health Asserts Demand For Its Compounded Weight Loss Offering To Continue Despite Resolved Supply Shortages
The FDA has resolved Eli Lilly's tirzepatide shortage, but localized supply issues persist. Meanwhile, Hims & Hers Health's Q3 2024 revenue is expected to exceed projections as concerns rise over compounded GLP-1 medications.
Hims & Hers shares tanked after regulators signaled new limits on the production of versions of weight-loss drugs.
Hims & Hers Health Inc (NYSE:HIMS) shares are trading lower Thursday after the U.S. Food and Drug Administration removed Eli ...
Anticipating a 35% CAGR in 2025, Hims & Hers is poised for substantial growth. Read why I maintain my strong buy rating on ...
U.S. telehealth company Hims & Hers Health on Wednesday said it will sell compounded versions of Novo Nordisk's popular ...
Bearish investors decided to classify Hims & Hers Health (HIMS) as an obesity drug supplier. HIMS stock lost 9.6% on Thursday after the U.S. Food and Drug Administration said that GLP-1, made by Eli ...
Spirit Airlines considering bankruptcy filing - WSJ. Port strike ends as dockworkers said to agree on tentative deal with 62% ...
Hims & Hers is making GLP-1 weight loss medications more accessible with a 50% discount for front-line heroes. Mihir Gandhi ...
Market-beating returns could be on the way for patient investors in these two up-and-coming healthcare growth stocks.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback